News | May 30, 2024
Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center
Greg was also central to the planning, design, and construction of this facility
Greg was also central to the planning, design, and construction of this facility
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Subscribe To Our Newsletter & Stay Updated
